LIVIVO - Search results -

Search results

Result 1 - 10 of total 23

Search options

Article ; Online: A new approach in monitoring blood tests in anti-tumour necrosis factor-α therapies in psoriasis.

Conti, Andrea / Paolinelli, Matteo

2023 Volume 190, Issue 4, Page(s) 463–464

MeSH term(s)	Humans ; Cost-Benefit Analysis ; Hematologic Tests ; Immunotherapy ; Psoriasis/drug therapy ; Necrosis
Language	English
Publishing date	2023-12-09
Publishing country	England
Document type	Editorial ; Comment
ZDB-ID	80076-4
ISSN	1365-2133 ; 0007-0963
ISSN (online)	1365-2133
ISSN	0007-0963
DOI	10.1093/bjd/ljad490
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui VI Zs.23: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Latest combination therapies in psoriasis: Narrative review of the literature.

Diotallevi, Federico / Paolinelli, Matteo / Radi, Giulia / Offidani, Annamaria

Dermatologic therapy

2022 Volume 35, Issue 10, Page(s) e15759

Abstract: Biological therapies revolutionized the treatment of many chronic inflammatory skin diseases, first of all psoriasis, thanks to their high efficacy and the reduced number of side effects. However, the use of a single biologic drug does not always provide ...

Abstract	Biological therapies revolutionized the treatment of many chronic inflammatory skin diseases, first of all psoriasis, thanks to their high efficacy and the reduced number of side effects. However, the use of a single biologic drug does not always provide complete control of the disease or associated comorbidities over time. The first biological drugs used for the treatment of psoriasis, tumor necrosis factor alpha inhibitors, have long been used in combination with traditional topical and systemic therapies to induce a complete remission of the disease that could not be achieved with innovative drug alone. Even with the advent of new biological therapies with more precise molecular targets, the challenge of using combination therapies remained. Psoriatic patients often have major comorbidities, such as arthritis, inflammatory bowel disease, uveitis or have other concomitant conditions such as chronic spontaneous urticaria and atopic dermatitis, which may require different biologic treatments than those indicated in psoriasis. The objective of this article is, through a comprehensive revision of the literature, to analyze in which cases the use of the combination of the latest therapies for psoriasis may be useful.
MeSH term(s)	Arthritis, Psoriatic/drug therapy ; Biological Products/adverse effects ; Humans ; Psoriasis/pathology ; Remission Induction ; Tumor Necrosis Factor-alpha
Chemical Substances	Biological Products ; Tumor Necrosis Factor-alpha
Language	English
Publishing date	2022-08-26
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1354801-3
ISSN	1529-8019 ; 1396-0296
ISSN (online)	1529-8019
ISSN	1396-0296
DOI	10.1111/dth.15759
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5181: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Pain Control during the Treatment of Primary Palmar Hyperhidrosis with Botulinum Toxin A by a Topical Application of Liposomal Lidocaine: Clinical Effectiveness.

Marani, Andrea / Gioacchini, Helena / Paolinelli, Matteo / Bobyr, Ivan / Martina, Emanuela / Radi, Giulia / Diotalallevi, Federico / Campanati, Anna

Toxins

2024 Volume 16, Issue 1

Abstract: Primary palmar hyperhidrosis (PPH) constitutes a debilitating condition that profoundly impacts the social, functional, and occupational aspects of individuals. The intradermal administration of botulinum toxin type A (BoNT-A) stands as an established ... ...

Abstract	Primary palmar hyperhidrosis (PPH) constitutes a debilitating condition that profoundly impacts the social, functional, and occupational aspects of individuals. The intradermal administration of botulinum toxin type A (BoNT-A) stands as an established therapeutic approach for PPH, albeit one frequently accompanied by considerable pain, posing challenges for patient tolerance. Our study aimed to assess the efficacy of combining cryoanalgesia spray (CA) with topical anesthesia utilizing a cream containing liposomal lidocaine at a concentration of 40 mg/g, with the objective of mitigating the pain associated with intradermal BoNT-A injection for PPH treatment. Nineteen participants, aged ≥18 years and afflicted with severe PPH, were enrolled in a double-blind randomized vehicle-controlled trial. Patient-perceived pain during the procedure was quantified using the Numeric Rating Scale (NRS). Statistical analysis was applied to the collected data. The combination of CA and the topical application of liposomal lidocaine during BoNT-A treatment for PPH resulted in diminished pain compared to CA alone and the combination of CA with the application of a basic cream. Topical anesthesia through the application of a liposomal lidocaine-containing cream emerged as a facile, secure, and efficacious approach for alleviating the pain associated with intradermal BoNT-A injection in PPH treatment. Furthermore, it demonstrated compatibility with CA, thereby offering a comprehensive strategy for pain management during BoNT-A administration.
MeSH term(s)	Humans ; Adolescent ; Adult ; Pain Management ; Botulinum Toxins, Type A/therapeutic use ; Lidocaine/therapeutic use ; Treatment Outcome ; Pain/drug therapy ; Liposomes ; Hyperhidrosis/drug therapy
Chemical Substances	Botulinum Toxins, Type A (EC 3.4.24.69) ; Lidocaine (98PI200987) ; Liposomes
Language	English
Publishing date	2024-01-06
Publishing country	Switzerland
Document type	Randomized Controlled Trial ; Journal Article
ZDB-ID	2518395-3
ISSN	2072-6651 ; 2072-6651
ISSN (online)	2072-6651
ISSN	2072-6651
DOI	10.3390/toxins16010028
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Novel Therapeutic Approaches and Targets for the Treatment of Neutrophilic Dermatoses, Management of Patients with Neutrophilic Dermatoses and Future Directions in the Era of Biologic Treatment.

Molinelli, Elisa / Brisigotti, Valerio / Paolinelli, Matteo / Offidani, Annamaria

Current pharmaceutical biotechnology

2020 Volume 22, Issue 1, Page(s) 46–58

Abstract: Neutrophilic dermatoses are a heterogeneous group of inflammatory skin disorders characterized by the presence of a sterile, predominantly neutrophilic infiltrate on histopathology. Universally accepted and validated guidelines for the management of ... ...

Abstract	Neutrophilic dermatoses are a heterogeneous group of inflammatory skin disorders characterized by the presence of a sterile, predominantly neutrophilic infiltrate on histopathology. Universally accepted and validated guidelines for the management of neutrophilic dermatoses do not exist, also given the paucity of randomized controlled study and high-quality data. However, the literature on the effective use of biologic therapies is rapidly expanding. This article reviews the epidemiology, clinical characteristics, histopathologic features, and management of pyoderma gangrenosum as well as Sweet's syndrome, sub-corneal pustular dermatoses and bowel-associated dermatosis arthritis syndrome. The use of biologic agents, including tumor necrosis factor α-inhibitors, anti-IL1, anti-IL-17, and IL-23 are discussed in detail.
MeSH term(s)	Anti-Inflammatory Agents/therapeutic use ; Antibodies, Monoclonal/therapeutic use ; Arthritis ; Humans ; Immunosuppressive Agents/therapeutic use ; Inflammation ; Neutrophil Infiltration/drug effects ; Neutrophils ; Pyoderma Gangrenosum/drug therapy ; Pyoderma Gangrenosum/immunology ; Pyoderma Gangrenosum/pathology ; Skin/drug effects ; Skin/immunology ; Skin/pathology ; Sweet Syndrome/drug therapy ; Sweet Syndrome/immunology ; Sweet Syndrome/pathology
Chemical Substances	Anti-Inflammatory Agents ; Antibodies, Monoclonal ; Immunosuppressive Agents
Language	English
Publishing date	2020-06-20
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	2132197-8
ISSN	1873-4316 ; 1389-2010
ISSN (online)	1873-4316
ISSN	1389-2010
DOI	10.2174/1389201021666200503050803
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6212: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art.

Diotallevi, Federico / Gioacchini, Helena / De Simoni, Edoardo / Marani, Andrea / Candelora, Matteo / Paolinelli, Matteo / Molinelli, Elisa / Offidani, Annamaria / Simonetti, Oriana

International journal of molecular sciences

2023 Volume 24, Issue 5

Abstract: Vitiligo is an acquired hypopigmentation of the skin due to a progressive selective loss of melanocytes; it has a prevalence of 1-2% and appears as rounded, well-demarcated white macules. The etiopathology of the disease has not been well defined, but ... ...

Abstract	Vitiligo is an acquired hypopigmentation of the skin due to a progressive selective loss of melanocytes; it has a prevalence of 1-2% and appears as rounded, well-demarcated white macules. The etiopathology of the disease has not been well defined, but multiple factors contribute to melanocyte loss: metabolic abnormalities, oxidative stress, inflammation, and autoimmunity. Therefore, a convergence theory was proposed that combines all existing theories into a comprehensive one in which several mechanisms contribute to the reduction of melanocyte viability. In addition, increasingly in-depth knowledge about the disease's pathogenetic processes has enabled the development of increasingly targeted therapeutic strategies with high efficacy and fewer side effects. The aim of this paper is, by conducting a narrative review of the literature, to analyze the pathogenesis of vitiligo and the most recent treatments available for this condition.
MeSH term(s)	Humans ; Vitiligo/etiology ; Hypopigmentation ; Melanocytes/metabolism ; Skin/metabolism ; Oxidative Stress
Language	English
Publishing date	2023-03-03
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms24054910
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Novel Therapeutic Approaches and Targets for Treatment of Chronic Urticaria: New Insights and Promising Targets for a Challenging Disease.

Martina, Emanuela / Diotallevi, Federico / Bianchelli, Tommaso / Paolinelli, Matteo / Offidani, Annamaria

Current pharmaceutical biotechnology

2020 Volume 22, Issue 1, Page(s) 32–45

Abstract: Background: Chronic Spontaneous Urticaria (CSU) is a disease characterized by the onset of wheals and/or angioedema over 6 weeks. The pathophysiology for CSU is very complex, involving mast cells and basophils with a multitude of inflammatory mediators. ...

Abstract	Background: Chronic Spontaneous Urticaria (CSU) is a disease characterized by the onset of wheals and/or angioedema over 6 weeks. The pathophysiology for CSU is very complex, involving mast cells and basophils with a multitude of inflammatory mediators. For many years the treatment of CSU has been based on the use of antihistamines, steroids and immunosuppressive agents with inconstant and frustrating results. The introduction of omalizumab, the only licensed biologic for antihistamine- refractory CSU, has changed the management of the disease. Objective: The aim of this article is to review the current state of the art of CSU, the real-life experience with omalizumab and the promising drugs that are under development. Methods: An electronic search was performed to identify studies, case reports, guidelines and reviews focused on the new targets for the treatment of chronic spontaneous urticaria, both approved or under investigation. The search was limited to articles published in peer-reviewed journals in the English Language in the PubMed database and trials registered in Clinicaltrials.gov. Results: Since the advent of omalizumab, the search for new therapies for chronic spontaneous urticaria has had a new impulse. Anti-IgE drugs will probably still be the cornerstone of therapy, but new targets may prove effective in syndromic urticaria or refractory cases. Conclusion: Although omalizumab has been a breakthrough in the treatment of CSU, many patients do not completely get benefit and even require more effective treatments. Novel drugs are under investigation with promising results.
MeSH term(s)	Anti-Allergic Agents/therapeutic use ; Antibodies, Monoclonal, Humanized/therapeutic use ; Chronic Urticaria/drug therapy ; Chronic Urticaria/immunology ; Histamine H1 Antagonists/therapeutic use ; Humans ; Immunosuppressive Agents/therapeutic use ; Molecular Targeted Therapy ; Omalizumab/therapeutic use
Chemical Substances	Anti-Allergic Agents ; Antibodies, Monoclonal, Humanized ; Histamine H1 Antagonists ; Immunosuppressive Agents ; Omalizumab (2P471X1Z11) ; ligelizumab (L8LE0L691T)
Language	English
Publishing date	2020-06-30
Publishing country	Netherlands
Document type	Journal Article ; Review
ZDB-ID	2132197-8
ISSN	1873-4316 ; 1389-2010
ISSN (online)	1873-4316
ISSN	1389-2010
DOI	10.2174/1389201021666200630140137
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6212: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The role of the optical super high magnification dermoscopy (O.S.H.M.D) in the management of melanocytic lesions.

Radi, Giulia / Rossi, Renato / Diotallevi, Federico / Giannoni, Melania / Molinelli, Elisa / Paolinelli, Matteo / Ferrara, Gerardo / Offidani, Annamaria

Journal of the European Academy of Dermatology and Venereology : JEADV

2022

Language	English
Publishing date	2022-08-17
Publishing country	England
Document type	Letter
ZDB-ID	1128828-0
ISSN	1468-3083 ; 0926-9959
ISSN (online)	1468-3083
ISSN	0926-9959
DOI	10.1111/jdv.18533
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3492: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 413: Show issues

Order via subito

Details ▾

Article ; Online: Metabolic, pharmacokinetic, and toxicological issues surrounding dapsone.

Molinelli, Elisa / Paolinelli, Matteo / Campanati, Anna / Brisigotti, Valerio / Offidani, Annamaria

Expert opinion on drug metabolism & toxicology

2019 Volume 15, Issue 5, Page(s) 367–379

Abstract: Introduction: In their 70-year history, dapsone and other sulfones have been used as both antibacterial and anti-inflammatory agents. Dapsone has been the main active principle in the multidrug regimen recommended by the World Health Organization for ... ...

Abstract	Introduction: In their 70-year history, dapsone and other sulfones have been used as both antibacterial and anti-inflammatory agents. Dapsone has been the main active principle in the multidrug regimen recommended by the World Health Organization for the treatment of leprosy. In addition, dapsone has been successfully used to treat a wide range of dermatological and systemic disorders, mostly characterized by neutrophilic and eosinophilic accumulation and infiltration. Areas covered: The PubMed database was searched using combinations of the following keywords: dapsone, sulfones, pharmacodynamics, pharmacology, adverse events, pharmacokinetics, drug interaction, dermatologic uses, and antimicrobial uses. This article reviews and updates the chemistry, pharmacokinetics, mechanism of action, adverse effects, drug interactions, and clinical application of sulfones. Expert opinion: Dapsone exhibits clinical efficacy in several cutaneous and systemic conditions and is now generally accepted as the therapy of choice for leprosy and for rare dermatosis, as dermatitis herpetiformis. Careful patient selection and close monitoring during treatment are mandatory to provide safe and effective use of dapsone. Familiarity with sulfones and dapsone is crucial because of this agent retains its niche in the clinician's therapeutic armamentarium.
MeSH term(s)	Animals ; Anti-Infective Agents/administration & dosage ; Anti-Infective Agents/adverse effects ; Anti-Infective Agents/pharmacokinetics ; Dapsone/administration & dosage ; Dapsone/adverse effects ; Dapsone/pharmacokinetics ; Drug Interactions ; Humans ; Leprostatic Agents/administration & dosage ; Leprostatic Agents/adverse effects ; Leprostatic Agents/pharmacokinetics ; Leprosy/drug therapy ; Skin Diseases/drug therapy
Chemical Substances	Anti-Infective Agents ; Leprostatic Agents ; Dapsone (8W5C518302)
Language	English
Publishing date	2019-04-19
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2214462-6
ISSN	1744-7607 ; 1742-5255
ISSN (online)	1744-7607
ISSN	1742-5255
DOI	10.1080/17425255.2019.1600670
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6264: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: The Role of Nutrition in Immune-Mediated, Inflammatory Skin Disease: A Narrative Review

Diotallevi, Federico / Campanati, Anna / Martina, Emanuela / Radi, Giulia / Paolinelli, Matteo / Marani, Andrea / Molinelli, Elisa / Candelora, Matteo / Taus, Marina / Galeazzi, Tiziana / Nicolai, Albano / Offidani, Annamaria

Nutrients. 2022 Jan. 29, v. 14, no. 3

2022

Abstract: Immune-mediated inflammatory skin diseases are characterized by a complex multifactorial etiology, in which genetic and environmental factors interact both in genesis and development of the disease. Nutrition is a complex and fascinating scenario, whose ... ...

Abstract	Immune-mediated inflammatory skin diseases are characterized by a complex multifactorial etiology, in which genetic and environmental factors interact both in genesis and development of the disease. Nutrition is a complex and fascinating scenario, whose pivotal role in induction, exacerbation, or amelioration of several human diseases has already been well documented. However, owing to the complexity of immune-mediated skin disease clinical course and breadth and variability of human nutrition, their correlation still remains an open debate in literature. It is therefore important for dermatologists to be aware about the scientific basis linking nutrition to inflammatory skin diseases such as psoriasis, atopic dermatitis, hidradenitis suppurativa, bullous diseases, vitiligo, and alopecia areata, and whether changes in diet can influence the clinical course of these diseases. The purpose of this narrative review is to address the role of nutrition in immune-mediated inflammatory skin diseases, in light of the most recent and validate knowledge on this topic. Moreover, whether specific dietary modifications could provide meaningful implementation in planning a therapeutic strategy for patients is evaluated, in accordance with regenerative medicine precepts, a healing-oriented medicine that considers the whole person, including all aspects of the lifestyle.
Keywords	alopecia ; atopic dermatitis ; diet ; disease course ; etiology ; human nutrition ; humans ; lifestyle ; medicine ; psoriasis ; therapeutics
Language	English
Dates of publication	2022-0129
Publishing place	Multidisciplinary Digital Publishing Institute
Document type	Article
ZDB-ID	2518386-2
ISSN	2072-6643
ISSN	2072-6643
DOI	10.3390/nu14030591
Database	NAL-Catalogue (AGRICOLA)

Order via subito

Article: Efficacy and Safety of Topical Calcipotriol 0.005% Versus Topical Clobetasol 0.05% in the Management of Alopecia Areata: An Intrasubject Pilot Study.

Molinelli, Elisa / Campanati, Anna / Brisigotti, Valerio / Sapigni, Claudia / Paolinelli, Matteo / Offidani, Annamaria

Dermatology and therapy

2020 Volume 10, Issue 3, Page(s) 515–521

Abstract: Introduction: Alopecia areata (AA) is a chronic inflammatory non-scarring type of hair loss. Current therapies for alopecia areata are rather limited and mainly involve the use of topical, intra-lesional or systemic steroids and topical immunotherapy, ... ...

Abstract	Introduction: Alopecia areata (AA) is a chronic inflammatory non-scarring type of hair loss. Current therapies for alopecia areata are rather limited and mainly involve the use of topical, intra-lesional or systemic steroids and topical immunotherapy, with variable benefit. Recent studies have demonstrated that vitamin D analogues could potentially promote hair growth in patients with patchy AA. Methods: We investigated the efficacy and safety of treatment with calcipotriol, a synthetic derivative of vitamin D (calcipotriol 0.005% ointment), versus treatment with the corticosteroid clobetasol (topical clobetasol 0.05% formulation), in a series of 35 patients with scalp AA, using an intrasubject design. Results: Patches treated with calcipotriol ointment showed greater and faster response rates than did those treated with topical clobetasol, although the differences were not statistically significant. The main strength of the study is its prospective design; the main limitation is the small number of participants. Conclusions: Treatment with the calcipotriol would appear to be reasonably effective in patients with mild to moderate patchy AA and was associated with only limited and reversible side effects.
Language	English
Publishing date	2020-04-27
Publishing country	Switzerland
Document type	Journal Article
ZDB-ID	2680284-3
ISSN	2190-9172 ; 2193-8210
ISSN (online)	2190-9172
ISSN	2193-8210
DOI	10.1007/s13555-020-00379-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

Order via subito

Details ▾
- Full text online
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

Order via subito